Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
soluble guanylate cyclase stimulator
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:2013
|
| gptkbp:brand |
gptkb:Adempas
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:contraindication |
pregnancy
severe hepatic impairment concomitant use of nitrates |
| gptkbp:developed_by |
gptkb:Boehringer_Ingelheim
|
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:effective_date |
FDA approved
|
| https://www.w3.org/2000/01/rdf-schema#label |
riociguat
|
| gptkbp:ingredients |
C22 H24 N4 O4 S
|
| gptkbp:is_atype_of |
C02 K X01
|
| gptkbp:is_used_for |
chronic thromboembolic pulmonary hypertension
pulmonary arterial hypertension |
| gptkbp:lifespan |
12 hours
|
| gptkbp:manager |
oral
|
| gptkbp:metabolism |
liver
|
| gptkbp:nutritional_value |
95%
|
| gptkbp:side_effect |
dizziness
headache nausea hypotension |
| gptkbp:type_of |
103169-84-4
|
| gptkbp:bfsParent |
gptkb:Adempas
|
| gptkbp:bfsLayer |
4
|